15th November 2019
Results of The Migraine Trust’s latest patient survey to inform new migraine drug NICE consultation
NICE opened the public consultation as it announced its initial decision is to not recommend Ajovy be made available on the NHS to treat migraine
The Migraine Trust will be using the results of our latest survey of patients in our response to NICE’s new consultation on the migraine drug Ajovy (Fremanezumab).
Ajovy, which is manufactured by Teva, is the latest CGRP (calcitonin gene-related peptide) antibody migraine medication to be appraised by the National Institute for Health and Care Excellence (NICE). NICE will decide whether it can be used by chronic migraine patients free of charge on the NHS in England.
NICE opened the public consultation today by announcing its initial decision is to not recommend Ajovy be made available on the NHS to treat migraine. This isn’t a surprise given that NICE also ruled in September against another CGRP drug, Aimovig (Erenumab), being used by the NHS in England, a decision which was then also adopted in Wales and Northern Ireland. However, the Scottish Medicines Consortium, the body that decides on whether a treatment can be available on the NHS in Scotland, did approve Aimovig for use by chronic migraine patients.
The Migraine Trust hopes that our new survey of people who have used CGPR antibody medication to treat migraine will help highlight the importance of these drugs being made available on the NHS. Over 200 people with chronic migraine completed the survey and the results demonstrate the life-changing impact the medication can have.
New generation of migraine medication
Ajovy is part of a new generation of migraine medication, the first preventive medication developed specifically to treat migraine.
Commenting on the NICE announcement, Gus Baldwin, Chief Executive of The Migraine Trust, said:
“It is very disappointing that in its initial decision NICE has not recommended Ajovy be made available to treat migraine on the NHS.
“We recently undertook a survey of people who have used CGRP antibody medication and for many this type of drug has been life-changing, allowing them to live in a way that they never thought possible.
“We look forward to sharing the results of our survey as part of the NICE consultation. We will also be making the results public for everyone to see.
“We hope the whole migraine community will now speak with one voice in asking NICE to approve this drug. We also hope that NICE and the drug manufacturer, Teva, will be able to reach an agreement over the price of the drug for the sake of chronic migraine patients who could benefit greatly from this new and effective drug treatment.”
Open to members of the public
The Migraine Trust is encouraging people affected by migraine and others involved in the care and treatment of migraine patients across England to take part in the NICE consultation. More information about the consultation can be found here.